Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics.
Antifungal plant defensin technology platform.
Safe and effective application of the plant defensin technology to the treatment of human fungal disease.
Share price, ASX announcements and investor resources.
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target.
View the full report (pdf)